Upregulation of CD9 in ovarian cancer is related to the induction of TNF-α gene expression and constitutive NF-κB activation

Carcinogenesis

Volumn 33, Issue 1, 2012, Pages 77-83

  Hwang, Jae Ryoung ^a   Jo, Kiwon ^b   Lee, Yoonna ^a   Sung, Byung Jun ^a   Park, Young Woo ^b   Lee, Je Ho ^a,c  

^a Sungkyunkwan University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD9 ANTIGEN; COMPLEMENTARY DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALB6; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER WEIGHT; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DISEASE SEVERITY; DNA MICROARRAY; EMBRYO; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; UPREGULATION;

EID: 84855395255     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr257     Document Type: Article

References (44)

1. Bignotti,E. et al. (2006) Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol. Oncol., 103, 405-416.
2. Santin,A.D. et al. (2004) Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int. J. Cancer, 112, 14-25.
3. Peters,D.G. et al. (2005) Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. Cancer Epidemiol. Biomarkers Prev., 14, 1717-1723.
4. Cook,G.A. et al. (1999) The tetraspanin cd9 influences the adhesion, spreading, and pericellular fibronectin matrix assembly of chinese hamster ovary cells on human plasma fibronectin. Exp. Cell Res., 251, 356-371.
5. Hemler,M.E. (2003) Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu. Rev. Cell Dev. Biol., 19, 397-422.
6. Le Naour,F. et al. (2000) Severely reduced female fertility in cd9-deficient mice. Science, 287, 319-321.
7. Ovalle,S. et al. (2007) The tetraspanin cd9 inhibits the proliferation and tumorigenicity of human colon carcinoma cells. Int. J. Cancer, 121, 2140-2152.
8. Huang,C.I. et al. (1998) Correlation of reduction in mrp-1/cd9 and kai1/cd82 expression with recurrences in breast cancer patients. Am. J. Pathol., 153, 973-983.
9. Miyake,M. et al. (1995) Motility related protein 1 (mrp-1/cd9) expression: inverse correlation with metastases in breast cancer. Cancer Res., 55, 4127-4131.
10. Saito,Y. et al. (2006) Absence of cd9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells. Cancer Res., 66, 9557-9565.
11. Funakoshi,T. et al. (2003) Expression of tetraspanins in human lung cancer cells: frequent downregulation of cd9 and its contribution to cell motility in small cell lung cancer. Oncogene, 22, 674-687.
12. Sho,M. et al. (1998) Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int. J. Cancer, 79, 509-516.
13. Erovic,B.M. et al. (2003) Motility-related protein-1/cd9 expression in head and neck squamous cell carcinoma. Head Neck, 25, 848-857.
14. Kohmo,S. et al. (2010) Cell surface tetraspanin cd9 mediates chemoresistance in small cell lung cancer. Cancer Res., 70, 8025-8035.
15. Nakamoto,T. et al. (2009) A novel therapeutic strategy with anti-cd9 antibody in gastric cancers. J. Gastroenterol., 44, 889-896.
16. Furuya,M. et al. (2005) Down-regulation of cd9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: morphologic alteration and reduced expression of beta1 integrin subsets. Cancer Res., 65, 2617-2625.
17. Houle,C.D. et al. (2002) Loss of expression and altered localization of kai1 and cd9 protein are associated with epithelial ovarian cancer progression. Gynecol. Oncol., 86, 69-78.
18. Drapkin,R. et al. (2004) Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia. Hum. Pathol., 35, 1014-1021.
19. Huang,C.L. et al. (2004) Mrp-1/cd9 gene transduction downregulates wnt signal pathways. Oncogene, 23, 7475-7483.
20. Yamazaki,H. et al. (2011) Regulation of cancer stem cell properties by CD9 in human b-acute lymphoblastic leukemia. Biochem. Biophys. Res. Commun, 409, 14-21.
21. Nishida,H. et al. (2009) Cd9 correlates with cancer stem cell potentials in human b-acute lymphoblastic leukemia cells. Biochem. Biophys. Res. Commun., 382, 57-62.
22. Biermann,K. et al. (2007) Gene expression profiling identifies new biological markers of neoplastic germ cells. Anticancer Res., 27, 3091-3100.
23. Tanaka,K. et al. (2009) Ddx1 is required for testicular tumorigenesis, partially through the transcriptional activation of 12p stem cell genes. Oncogene, 28, 2142-2151.
24. Kim,Y.J. et al. (2007) Role of cd9 in proliferation and proangiogenic action of human adipose-derived mesenchymal stem cells. Pflugers Arch., 455, 283-296.
25. Libermann,T.A. et al. (1990) Activation of interleukin-6 gene expression through the nf-kappa b transcription factor. Mol. Cell. Biol., 10, 2327-2334.
26. Balkwill,F. (2009) Tumour necrosis factor and cancer. Nat. Rev. Cancer, 9, 361-371.
27. Smith,T.A. (2010) Towards detecting the her-2 receptor and metabolic changes induced by her-2-targeted therapies using medical imaging. Br. J. Radiol., 83, 638-644.
28. Konner,J.A. et al. (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase i study. Clin. Cancer Res., 16, 5288-5295.
29. Yoshida,H. et al. (2011) Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer. Anticancer Res., 31, 1271-1277.
30. Kim,C.J. et al. (2011) High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma. Eur. J. Cancer, 47, 918-925.
31. Sheng,Q. et al. (2011) The therapeutic potential of targeting the egfr family in epithelial ovarian cancer. Br. J. Cancer, 104, 1241-1245.
32. Piura,B. et al. (2009) Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma. J. Oncol., 2009, 581939.
33. Balkwill,F. et al. (2010) Tnf: a tumor-suppressing factor or a tumorpromoting factor? Future Oncol., 6, 1833-1836.
34. Balkwill,F. (2006) Tnf-alpha in promotion and progression of cancer. Cancer Metastasis Rev., 25, 409-416.
35. Lu,T. et al. (2004) Cytokine overexpression and constitutive nfkappab in cancer. Cell Cycle, 3, 1114-1117.
36. Cao,L. et al. (2008) Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis, 29, 1893-1900.
37. Sun,C. et al. (2007) Aurora kinase inhibition downregulates nf-kappab and sensitises tumour cells to chemotherapeutic agents. Biochem. Biophys. Res. Commun., 352, 220-225.
38. Kim,D.S. et al. (2007) Saxatilin inhibits tnf-alpha-induced proliferation by suppressing ap-1-dependent il-8 expression in the ovarian cancer cell line mdah 2774. Mol. Immunol., 44, 1409-1416.
39. Darb-Esfahani,S. et al. (2010) Expression of classical nf-kappab pathway effectors in human ovarian carcinoma. Histopathology, 56, 727-739.
40. Nilsson,M.B. et al. (2005) Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res., 65, 10794-10800.
41. McCluggage,W.G. (2010) The pathology of and controversial aspects of ovarian borderline tumours. Curr. Opin. Oncol., 22, 462-472.
42. Pasquet,M. et al. (2010) Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int. J. Cancer, 126, 2090-2101.
43. Yunta,M. et al. (2003) Tetraspanin proteins as organisers of membrane microdomains and signalling complexes. Cell. Signal., 15, 559-564.
44. Moseley,G.W. (2005) Tetraspanin-fc receptor interactions. Platelets, 16, 3-12.